The first #SITC24 poster session is underway! We’re excited to have over 20 Moffitt posters featured. Be sure to stop by if you’re attending. #MoffittSITC24 Society for Immunotherapy of Cancer

Live from #SITC24, I'm joined by John Mullinax (John E. Mullinax, MD, FACS) to discuss the latest work happening in #sarcoma, including his own #TILTherapy trial. Society for Immunotherapy of Cancer #MoffittSITC24 Watch the video to learn more. 👇

LIVE from #SITC24, Justin Miller (Justin Miller ) joins us to discuss a retrospective analysis of enrollment challenges in a phase I non-muscle invasive #bladdercancer clinical trial. #MoffittSITC24 Society for Immunotherapy of Cancer USF Health Medicine Learn more ➡️ bit.ly/48MYCbZ

What an accomplishment for a second year USF Health med student! Mentored by trial PI Michael Poch and correlative work by recent SPT Lab graduate student Sarah Bazargan, this innovative clinical trial involves local delivery of TIL: a whole new frontier.

At #SITC24, Justin Miller (Justin Miller) presents a Moffit led trial on autologous TIL therapy in BCG-exposed non-muscle invasive #bladdercancer . #MoffittSITC24 Society for Immunotherapy of Cancer Learn more ➡️ bit.ly/4es95uC

During #SITC24 Moffitt’s Roger Li, MD (Roger Li) discusses the combination of oncolytic virotherapy and nivolumab (C+N) as a therapy for cisplatin-ineligible muscle-invasive bladder cancer (MIBC). #MoffittSITC24 Society for Immunotherapy of Cancer  ➡️ Combination neoadjuvant treatment using Creto +

🚨 A comprehensive review on Immune-Based and Novel Therapies in Variant Histology Renal Cell Carcinomas lead by super 🌟 Justin Miller Moffitt Research 🌟 pubmed.ncbi.nlm.nih.gov/39858107/

Tomorrow at ASCO #GU25: Jeffrey Johnson, MD presents an updated efficacy, safety, and correlative analysis of a phase II trial in metastatic renal cell carcinoma with coordinated pembrolizumab and high dose IL-2. Read more: bit.ly/4jVn4x5 ASCO

Join Adnan Fazili, MD tomorrow at ASCO #GU25 as he presents on using geospatial analysis with multiplex immunofluorescence to analyze tumor immune microenvironment patterns and prognosis in penile cancer. Read more: bit.ly/4b2uCdj ASCO

Join Justin Miller (Justin Miller) tomorrow at ASCO #GU25 as he presents FGD1 splice variants as predictors of brain and bone metastatic organotropism in clear cell renal cell carcinoma. Read more: bit.ly/411Fxzi ASCO

At ASCO #GU25, Christopher Guske (Chris Guske) discusses the feasibility of tumor-infiltrating lymphocyte (#TIL) expansion in non-clear cell renal cell carcinoma. Read more: bit.ly/3EzqFRo ASCO USF Health Medicine

Join Jad Chahoud, MD (jc) tomorrow at ASCO #GU25 as he discusses optimizing clear cell renal cell carcinoma tumor-infiltrating lymphocytes under controlled hypoxic conditions. Read more: bit.ly/40XU7bc ASCO

🚀 Exciting news! @Moffittnews is teaming up with 1st Biotherapeutics to accelerate the future of cancer treatment, starting w/ the development of 1ST Bio’s FB849 HPK1 inhibitor, a novel immuno-oncology agent. jc moffitt.org/newsroom/news-…

‼️🚨A Contemporary Review on Immune-Based and Novel Therapies in Variant Histology Renal Cell Carcinomas by ⭐️⁦Moffitt Hematology/Oncology Fellowship⁩ ⁦Justin Miller⁩ #JeffJhonson ⁦Chris Guske⁩ ⁦Moffitt Cancer Center⁩ mdpi.com/2072-6694/17/2…

Huge thanks to our amazing team! Our paper highlights contemporary trial results across #RCC histologies, racial/ethnic disparities in diagnosis and treatment, and personalized therapeutic strategies for variant subtypes. #KidneyCancer #oncology Moffitt Cancer Center Cancers MDPI

🔬Check out the #Review "Immune-Based and Novel Therapies in Variant Histology Renal Cell Carcinomas" ✍️by Justin Miller jc et al. Moffitt Cancer Center Read more here👉mdpi.com/2072-6694/17/2…

x.com/i/article/1892…